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Abstract
While increased serum concentrations of CXCL9/10 are associated with acute cellular rejection (ACR) occurrence, the association
between CXCL9/10 single nucleotide polymorphisms (SNPs) and ACR after liver transplantation (LT) remains unknown.
In the present case-control study, polymorphisms of CXCL9 (rs10336) and CXCL10 (rs3921) were determined by polymerase
chain reaction in 215 liver transplant recipients. ACR was deﬁned as biopsy proven within 6 months after LT. As selected SNPs were
in 3’-UTR region, their possible association with protein synthesis was assessed by measuring the plasma concentration of CXCL9/
10 in a cohort of 40 new transplant patients using ELISA.
There was no association between CXCL9/10 genotypes and overall incidence of ACR. However, patients with CXCL9 genotype
AA developed ACR earlier than patients with GG genotype (P= .003), with similar results for CXCL10 gene (CC vs GG; P= .005).
There was no statistically signiﬁcant difference in plasma concentrations of CXCL9/10 between the rejectors and the non-rejectors.
Of note, patients with AA CXCL9 genotype had signiﬁcantly higher CXCL9 plasma concentrations than patients with AG (P= .01) or
GG genotype (P= .045).
In conclusion, the SNPs of CXCL9 (rs10336) and CXCL10 (rs3921) are not associated with the incidence of ACR. However,
patients with CXCL9 genotype AA developed ACR earlier and the same genotype was associated with greater plasma
concentrations suggesting the involvement of CXCL9 mediated processes in ACR development.
Abbreviations: ACR = acute cellular rejection, ALD = alcoholic liver disease, ALT = alanine aminotransferase, AST = aspartate
aminotransferase, BMT = bone marrow transplantation, BPAR = biopsy-proven acute rejection, CXCL10 = C-X-C motif chemokine
ligand 10, CXCL9 = C-X-C motif chemokine ligand 9, CXCR3 = C-X-C motif chemokine receptor 3, DNA = deoxyribonucleic acid,
ELISA = enzyme linked immunosorbent assay, IL = interleukin, IQR = interquartile range, LT = liver transplantation, MAF = minor
allele frequency, MELD = model end-stage liver disease, mRNA = messenger ribonucleic acid, PCR = polymerase chain reaction,
SNP = single nucleotide polymorphism, TGFB = transforming growth factor beta.
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Despite the improvement and optimization of immunosuppres-
sive protocols, acute cellular rejection (ACR) remains a common
complication after liver transplantation (LT) that occurs in about
10% to 30% of transplant patients.[1,2] Contrary to previousEditor: Sherief Abd-Elsalam.
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1data, a recently conducted study on a large number of recipients
showed that ACR is a clinically signiﬁcant event, which is
associated with an increased risk of graft failure and death after
LT.[1] Furthermore, clinical predisposing factors, such as younger
recipient age, lack of renal impairment, higher AST levels before
LT, longer cold ischemic times and older donors, do not entirely
explain the risk for ACR occurrence.[2] Following the ﬁndings
that immune mediators played a key role in ACR pathogenesis, it
was hypothesized that single nucleotide polymorphisms (SNPs)
of various cytokine and chemokine genes might be a predisposing
factor for ACR occurrence or severity. Indeed, it was
subsequently reported that certain SNPs of cytokine genes such
as interleukin (IL) IL-4 T-33C polymorphism, IL-6 G-174C
polymorphism, interferon gamma T + 874A polymorphism and
transforming growth factor beta (TGFB) + 869 gene polymor-
phism are associated with altered susceptibility to ACR.[3–5]
Findings of recent studies suggest that cytokine CXCL9 might
be a useful prognostic factor for ACR occurrence. Asaoka et al
reported that intragraft expression levels of CXCL9 mRNA are
increased during the ACR, while Raschzok et al found that
CXCL9 serum concentrations were increased preoperatively and
at the ﬁrst postoperative day in patients who subsequently
developed ACR.[6,7] An association between the serum levels of
CXCL9 and CXCL10 and the development of early allograft
dysfunction was also reported.[8] Furthermore, CXCL9 and
CXCL10 polymorphisms were shown to be associated with
diseases such as rheumatoid arthritis or Chagas cardiomyopathy,
both conditions where T-cell response plays an important
role.[9,10] However, the association between CXCL9 and
Ostojic et al. Medicine (2019) 98:8 MedicineCXCL10 polymorphisms and ACR after LT has not been
investigated to the best of our knowledge. Therefore, the primary
aim of our study was to assess possible associations between
CXCL9 (rs10336) and CXCL10 (rs3921) polymorphisms and
the incidence of ACR, while, as a secondary aim, we assessed
associations between the polymorphisms, chemokine levels, and
the time of ACR occurrence.2. Patients and methods
2.1. Patients
This study included 215 adult liver transplant recipients (see
Diagram 1, http://links.lww.com/MD/C832) who underwent LT
due to alcoholic liver disease (ALD) between January 2009 and June
2017 at the Merkur University Hospital, Zagreb, Croatia. All
subjects were of Caucasian ethnic origin and had no other or
concomitant liver etiologies (viral, autoimmune, metabolic, crypto-
genic, etc.).Recipientswithmulti-organ transplantationsorprevious
solid-organ transplantations were excluded. The study was
performedaccording to theprinciples of theDeclarationofHelsinki.
The Hospital Ethics Committee approved the protocol in 2016.
Patients that underwent transplantation before the start of the study
were recruited during their regular checkups, while 40 new
transplant patients were recruited at 3rd to 4th post-transplantation
week (median 23rd (20–28) post-transplantation day). After
obtaining informed, written consent to participate in the study,
venous blood samples were taken and stored at 20°C until DNA
isolation and gene analysis. Additionally, plasma was obtained by
centrifugation from samples collected from new transplant patients
and stored at20°C until analysis. Data on age, sex, MELD score,
AST, ALT, immunosuppressive therapy, date of transplantation,
and date of acute rejection, where applicable, were collected from
patients’ records. All liver transplant recipients received the same
immunosuppressive protocol according to standard clinical practice
at our institution. Induction immunosuppressive therapy consisted
of steroids, which were gradually tapered in the maintenance
protocol during the ﬁrst 3 months and then discontinued. A
combination of calcineurin inhibitors (cyclosporine or tacrolimus)
andmycophenolatemofetil (3gdaily)wasused fromthe start and/or
modiﬁed in case of side effects. The dose of calcineurin inhibitorwas
adjusted according to the blood drug levels.2.2. Acute cellular rejection
For the purpose of analysis, subjects were classiﬁed into 2 groups
(ACR and non-ACR) according to biopsy-proven acute rejection
(BPAR) episodes. Episodes of ACR were deﬁned by typical
histopathological features of Banff score ≥3 within the ﬁrst 6
months after LT.[11] Liver biopsies were performed as clinically
indicated based on an increase of liver enzymes and interpreted
by an independent transplant pathologist. All patients responded
well to an anti-rejection high-dose corticosteroid therapy and/or
increase in calcineurin inhibitors.2.3. Genotyping
DNAwas extracted from the whole blood samples (200 ul) using
QIAGEN QIAamp DNA Blood Mini Kit spin procedure
according to manufacturer’s instructions. DNA concentration
and quality were determined using NanoDrop ND1000
Spectrophotometer. All samples were stored at 20°C until
batch analysis. Genotypes were determined by polymerase chain2reaction (PCR) analysis using commercially available TaqMan
SNP assays for CXCL9 (rs10336) and CXCL10 (rs3921) with
ABI 7500 instrument (Applied Biosystems).
CXCL9 and CXCL10 SNPs were selected based on the data of
Hapmap (available at manufacturer’s website: https://www.
thermoﬁsher.com/order/genome-database/details/genotyping/
C____486222_10?CID=&ICID=&subtype, https://www.ther
moﬁsher.com/order/genome-database/details/genotyping/
C____497062_10?CID=&ICID=&subtype&equals; and NCBI
(https://www.ncbi.nlm.nih.gov/projects/SNP) with minor allele
frequency greater than 20% in European population.2.4. Enzyme linked immunosorbent assay (ELISA)
ConcentrationsofCXCL9andCXCL10 inplasmaweredetermined
by ELISA using commercially available kits (DCX900 cat number
for CXCL9, DIP100 cat number for CXCL10, R&D Systems) in
accordance with manufacturer’s instructions.2.5. Statistical analysis
Continuous variables are presented as median with interquartile
range (IQR) or mean± standard error (SEM) and compared by
using Mann–Whitney/Kruskal–Wallis test or Student t test/
ANOVA, as appropriate. Post-hoc multiple comparison correc-
tions were applied to control the family-wise error rate.
Categorical data were compared using Chi-Squared test, while
Kendall tau (t) test was used for correlation assessment.
Genotype frequencies of all polymorphisms were tested for
Hardy–Weinberg equilibrium. For genotype analysis we tested
dominant, recessive, overdominant, and codominant model.
Linear regression models were built with recipient and donor age,
MELD score, sex, and CXCL9 or CXCL10 genotypes as
independent predictors to estimate their association with the time
of ACR. For all calculations, P value< .05 was deﬁned as
statistically signiﬁcant. Statistical analyses were performed using
free online software SNPStats (http://bioinfo.iconcologia.net/
snpstats) and R (a language and environment for statistical
computing, R Foundation for Statistical Computing, Vienna,
Austria) with ﬁgures plotted in GraphPad Prism version 6 for
Windows (GraphPad Software Inc., La Jolla, CA).3. Results
3.1. General characteristic of patients with and without
ACR
A total of 215 adult alcohol-related liver transplant recipients
were divided into 2 groups; ACR 59 (27.4%) and non-ACR 156
(72.6%). There were no signiﬁcant differences in pre-transplant
recipients’ parameters regarding age, sex, creatinine, AST and
ALT levels, or type of immunosuppression after LT, between the
rejection and non-rejection group (Table 1). However, patients
that developed ACR had signiﬁcantly higher MELD scores
(P= .036) pre-LT and received signiﬁcantly younger liver grafts
(56.4±1.8 vs 62.5±1.1, P= .005; Table 1). The median time
from LT to rejection was 7 (IQR=5–10) days.3.2. CXCL9 and CXCL10 genotypes are not associated
with ACR incidence
The genotype and allele frequencies of liver transplant recipients
are summarized in Table 2. Genotypes were in Hardy–Weinberg
Table 1
General characteristic of patients with and without ACR.
Characteristics ACR Non-ACR
Recipient n=59 n=156 P value
Age (years) 56.7±0.9 58.7±0.6 .07
Sex
Females 8 (13.6) 22 (14.1) .92
Males 51 (86.4) 134 (85.9)
Pre-transplant
MELD 17.0 (14.0–21.0) 15.0 (12.0–18.0) .036
Creatinine (umol/L) 75.0 (59.0–104.0) 82.0 (59.5–102.0) .61
AST (IU/l) 52.0 (45.0–72.0) 50.0 (37.5–64.0) .39
ALT (IU/l) 29.0 (20.0–41.0) 29.0 (21.0–39.5) .88
HCC 11 (19.0) 41 (26.3) .27
Initial immunosuppression
CYA+MMF+S 32 (56.1) 94 (60.6) .55
TAC+MMF+S 25 (43.9) 61 (39.4)
Donor
Age (years) 56.4±1.8 62.5±1.1 .005
Sex
Females 17 (28.8) 52 (33.3) .53
Males 42 (71.2) 104 (66.7)
Data are presented as mean±SEM or as median (interquartile range) or N (%).
ACR= acute cellular rejection, ALT= alanine aminotransferase, AST=aspartate aminotransferase, CYA= cyclosporin, HCC=hepatocellular carcinoma, MELD=Model End Stage Liver Disease, MMF=
mycophenolate mofetil, S= steroid, TAC= tacrolimus.
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strong linkage disequilibrium (D’= .99, r= .986) between
CXCL9 and CXCL10.
In the rejection group, 22 (37.3%) patients had GG, 25
(42.4%) had AG and 12 (20.3%) had AA genotype of the
CXCL9 polymorphism, with similar genotype distribution
observed in the non-rejection group, where 54 (34.6%) patients
had GG, 75 (48.1%) had AG and 27 (17.3%) had AA genotype.
Lack of association between CXCL9 genotypes and incidence of
ACR was found in codominant, dominant, recessive, overdomi-Table 2
CXCL9 and 10 genotypes compared to acute cellular rejection occu
Gene SNP Model Genotype
CXCL9 (rs10336) Codominant GG 22
AG 25
AA 12
Dominant GG 22
AG+AA 37
Recessive GG+AG 47
AA 12
Overdominant GG+AA 34
AG 25
Log additive
CXCL10 (rs3921)
∗
Codominant GG 21
CG 26
CC 12
Dominant GG 21
CG+CC 38
Recessive GG+CG 47
CC 12
Overdominant GG+CC 33
CG 26
Log additive
Data are presented as N (%) or median (interquartile range).
ACR= acute cellular rejection, CXCL10=C-X-C motif chemokine ligand 10, CXCL9=C-X-C motif chem
∗
One sample was repeatedly undeterminable.
3nant and log-additive model (P> .05) (Table 2). Similar results
were obtained for CXCL10 genotypes (Table 2).3.3. CXCL9 genotype is associated with the time until
rejection and CXCL9 concentration in plasma
Even though there was no connection between the examined
polymorphisms and ACR occurrence, we observed a signiﬁcant
association between both CXCL9 and CXCL10 genotypes and
the time of ACR occurrence. Patients with CXCL9 genotype AArrence.
Acute rejection
Yes No OR P
(37.3%) 54 (34.6%) 1.00
(42.4%) 75 (48.1%) 0.82 (0.42–1.60) .74
(20.3%) 27 (17.3%) 1.09 (0.47–2.53)
(37.3%) 54 (34.6%) 1.00
(62.7%) 102 (65.4%) 0.89 (0.48–1.66) .72
(79.7%) 129 (82.7%) 1.00
(20.3%) 27 (17.3%) 1.22 (0.57–2.60) .61
(57.6%) 81 (51.9%) 1.00
(42.4%) 75 (48.1%) 0.79 (0.43–1.45) .45
1.01 (0.66–1.53) .97
(35.6%) 52 (33.5%) 1.00
(44.1%) 76 (49%) 0.85 (0.43–1.66) .79
(20.3%) 27 (17.4%) 1.10 (0.47–2.57)
(35.6%) 52 (33.5%) 1.00
(64.4%) 103 (66.5%) 0.91 (0.49–1.71) .78
(79.7%) 128 (82.6%) 1.00
(20.3%) 27 (17.4%) 1.21 (0.57–2.58) .62
(55.9%) 79 (51%) 1.00
(44.1%) 76 (49%) 0.82 (0.45–1.50) .52
1.02 (0.67–1.56) .94
okine ligand 9.
Table 3
Comparison of the grade of ACR according to Banff criteria, MELD score, and time of ACR occurrencewith genotypes for CXCL 9 and 10.
CXCL9 CXCL10
A/A A/G G/G P C/C C/G G/G P
Time to ACR (days) 5 (4–7.5) 6 (6–9) 8 (6–18.25) .004 5 (4–7.5) 6.5 (6–9.25) 8 (6–14.5) .008
MELD 15 (13.3–17.8) 18 (14–22) 16.5 (15–22.3) .233 15 (13.3–17.8) 18 (14.5–23.3) 16 (15–22) .171
RAI 4 (3–4.75) 4 (4–5) 4 (3–4.25) .311 4 (3–4.75) 4 (4–5) 4 (3–4.5) .309
Data are presented as median (interquartile range). Comparisons were made by Kruskal–Wallis test followed by post-hoc procedures with Bonferroni adjustment for multiple comparisons.
ACR= acute cellular rejection, CXCL10=C-X-C motif chemokine ligand 10, CXCL9=C-X-C motif chemokine ligand 9, MELD=Model End Stage Liver Disease, RAI= rejection activity index.
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patients with the GG genotype (median 8 days, IQR=6–18.3;
Bonferroni adjusted P= .003), with similar results for CXCL10
gene (CC vs GG; Bonferroni adjusted P= .005; Table 3). No
signiﬁcant differences were observed in MELD or RAI score
across different genotypes of CXCL 9–10 in ACR patients
(Table 3). In addition, there were no associations either between
RAI score and the time of ACR (Kendall t=0.09; P= .40) or
between the type of the initial immunosuppression and the time
of ACR (Mann–Whitney, P= .11). To assess whether CXCL9 or
CXCL10 genotype is an independent predictor of the time of
ACR occurrence, we constructed a linear regression model with
donor and recipient age, sex, MELD score, and genotype
included as predicting variables. CXCL9 genotype remained a
signiﬁcant predictor of the time until ACR event, even after theFigure 1. CXCL9 and CXCL10 concentration in plasma in a cohort of 40 new trans
ELISA. A and B show a comparison of plasma CXCL9/10 levels between patients w
in plasma. D and E Association between CXCL9/10 genotypes and their protein
rejection, CXCL10=C-X-C motif chemokine ligand 10, CXCL9=C-X-C motif che
4addition of age, sex and MELD to analysis (b=0.283; P= .033),
while CXCL10 genotype was not signiﬁcant (b=0.222; P
= .096).
Finally, we analyzed the plasma concentration of CXCL9 and
CXCL10 in a cohort of 40 new transplant patients. There was no
statistically signiﬁcant difference between the rejectors and the
non-rejectors for either of the analyzed chemokines (P= .78 and
P= .68, respectively, Fig. 1A–B) with positive correlation
between CXCL9 andCXCL10 concentrations (r=0.35, P= .028,
Fig. 1C). Interestingly, patients with AA CXCL9 genotype had
signiﬁcantly higher CXCL9 concentration (151.65±22.74pg/
ml) in plasma than patients with AG (56.49±16.31pg/ml,
P= .01) or GG genotype (87.1±16.23pg/ml, P= .045; Fig. 1D).
There was no association between CXCL10 genotypes and
CXCL10 concentration (Fig. 1E).plant patients. CXCL9 and CXCL10 plasma concentrations were determined by
ith and without rejection episodes. C Correlation between the CXCL9/10 levels
levels in plasma. Data represents mean±standard error. ACR=acute cellular
mokine ligand 9.
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In this study, we analyzed the associations between CXCL9 and
CX10 polymorphisms and ACR after LT. There were no
signiﬁcant associations between CXCL9 and CXCL10 gene
polymorphisms and ACR development. However, patients with
CXCL9 genotype AA developed ACR earlier and the same
genotype was associated with greater CXCL9 plasma levels,
suggesting the involvement of CXCL9 mediated processes in the
ACR development.
Our analysis of clinical risk factors for ACR showed an
association between ACR and younger donor age. This is in
agreement with the study by Onaca et al, which showed that
patients age >60 had a higher incidence of ACR when receiving
organs from donors <50 years of age.[12] The most likely
explanation relates to the fact that the immune response
gradually decreases with age, and that grafts from younger
donors are more immunogenic. However, a more recent study
investigating the impact of using elderly donors (>60 years) did
not ﬁnd a signiﬁcant association between donor age and
incidence of ACR.[13] These discrepancies regarding donor age
and ACR are probably due to possible interactions between
donor age and other risk factor affecting ACR such as recipient
age, etiology of liver disease or induction with IL-2 receptor
antagonist.[14] Our results also show an association between
higherMELD score and ACR. However, lack of models and data
regarding this connection, as well as its questionable biological
relevance and plausibility, demands cautious interpretation, and
warrants further research into this topic.
To our knowledge, this is the ﬁrst study that investigated the
association between CXCL9 (rs10336) and CXCL10 (rs3921)
SNPs and solid-organ graft rejection. So far, CXCL9 and CXC10
gene polymorphisms were investigated in hepatic ﬁbrosis, several
autoimmune diseases, infectious diseases, and bone marrow
transplantation (BMT). Bruck et al studied SNPs of CXCL9
(rs10336, rs3733236) and CXCL10 (rs3921, rs35795399, and
rs8878) genes in patients with diabetes type I and found no
associations in German population.[15] Kotrych et al examined
the associations of CXCL9 (rs3733236) and CXCL10 (rs8878)
polymorphisms with rheumatoid arthritis, showing that
CXCL10 GG genotype carriers had signiﬁcantly higher frequen-
cy of extra-articular manifestations vs AA+AG carriers.[9]
Association between the CXCL9–11 (rs10336 for CXCL9,
rs3921 for CXCL10, and rs4619915 for CXCL11) polymor-
phisms and hepatic ﬁbrosis was ﬁrst reported in HIV/HCV-
coinfected patients by Pineda et al.[16] Recently, Jimenez-Sousa
et al analyzed the association between CXCL9–11 (rs10336 for
CXCL9, rs3921 for CXCL10, and rs4619915 for CXCL11)
polymorphisms and liver ﬁbrosis in HCV-infected patients,
further supporting their association with the likelihood of hepatic
ﬁbrosis.[17] In transplantation medicine, the impact of an SNP
(rs3921) in the CXCL10 gene was studied regarding the
outcomes in patients who underwent BMT for hematologic
malignancies. The carriers of C/G or G/G genotypes had a
signiﬁcantly better 5-year survival rate and lower transplant-
related mortality than the C/C genotype carriers.[18] In agreement
with the ﬁndings of Pineda-Tenor et al, we found strong linkage
disequilibrium between the CXCL9 and CXCL10 genotypes.[16]
Raschzok et al reported that patients who developed ACR had
elevated plasma levels of CXCL9 before the transplantation and
at ﬁrst post-operative day.[7] Aiming to investigate if there were
any long-term CXCL9/10 elevations, we measured CXCL9/10
levels at a later point in time—in the third to fourth post-5transplantation week and found no difference in CXCL9/10
levels between the rejectors and non-rejectors. This can probably
be attributed to a good response to the ACR therapy.
Unfortunately, we have not taken samples at earlier points in
time to conﬁrm this hypothesis.
We found a signiﬁcant association between CXCL9/10
genotypes and the time of ACR occurrence. The median time
until ﬁrst ACR episode was 7 days, which is consistent with the
data in previous studies.[2] However, patients with CXCL9
genotype AA and CXCL10 genotype CC developed ACR earlier
than patients with the CXCL9 and 10 GG genotypes,
respectively. In the regression analysis only CXCL9 genotype
AA has been identiﬁed as an independent predictor of time to
ACR. In line with this, we found greater levels of CXCL9 in the
plasma of patients with AA genotype. To the best of our
knowledge, this is the ﬁrst study that analyzed the association
between these CXCL9/10 gene polymorphisms and their
concentration in plasma. Since studies on animal models showed
that CXCL9 accelerates acute transplant rejection our ﬁnding of
greater CXCL9 concentrations in genotype (AA) associated with
earlier ACR occurrence seems plausible.[19]
This study has several limitations that should be considered
carefully. As one of the main conclusions of the study suggests
that there is no association between the ACR incidence and
chemokine genotypes, the question of power should be
addressed. The number of patients is equal or moderately lower
than the number of patients in similar studies. It should be taken
into account that minor allele frequency (MAF) for both selected
genotypes is high (41.4% and 42.1% for CXCL9 and CXCL10
genotype, respectively), which considerably reduces the number
of patients needed to reach speciﬁc power. Similar studies with
positive ﬁndings report relativeMAF difference between rejectors
and non-rejectors between 40% and 50%.[5,20] Taking these
limits into account, the calculated power of our studywas 65% to
85%. Furthermore, as the P values for different models range
between .42 and .97 and are far from the signiﬁcance threshold of
.05, it is highly unlikely that inclusion of an additional number of
patients would change the conclusion that there is a lack of
association between the ACR and studied genotypes. However, it
should be noted that we tested only one polymorphism of each
gene and no conclusions can bemade regarding the other variants
of CXCL9 and 10 genes. Furthermore, we have not analyzed the
expression of CXCL9/10 ligand CXCR3, which might have an
inﬂuence on the interpretation of data. As only patients
transplanted due to end stage of alcoholic disease were included
in the study, the result cannot be generalized to other indications.
Finally, protocolled biopsies were not performed at our center,
thus this study did not include subclinical rejection episodes.
In conclusion, despite previous evidence regarding the associa-
tion of serum levels CXCL 9 and 10 with ACR, here, we report no
connection between the CXCL9 rs10336 and CXCL10 rs3921
polymorphisms and ACR in the later course. However, CXCL9
rs10336 AA genotype is associated with earlier ACR occurrence
and greater CXCL9 concentrations in plasma.
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